Cipla shines on reporting consolidated net profit of Rs 178.61 crore in Q4

Cipla Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500087 | NSE: CIPLA

23 May 2018 Evaluate

Cipla is currently trading at Rs. 540.95, up by 16.60 points or 3.17% from its previous closing of Rs. 524.35 on the BSE.

The scrip opened at Rs. 524.00 and has touched a high and low of Rs. 562.50 and Rs. 519.75 respectively. So far 297231 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 663.00 on 07-Nov-2017 and a 52 week low of Rs. 479.00 on 26-May-2017.

Last one week high and low of the scrip stood at Rs. 562.50 and Rs. 508.10 respectively. The current market cap of the company is Rs. 43106.08 crore.

The promoters holding in the company stood at 37.21%, while Institutions and Non-Institutions held 38.10% and 24.69% respectively.

Cipla has reported over 8-fold jump in its net profit at Rs 224.81 crore for the quarter ended March 31, 2018 as compared to Rs 25.86 crore for the same quarter in the previous year. Total income of the company increased by 2.65% at Rs 2,788.22 crore for quarter under review as compared to Rs 2,716.36 crore for the quarter ended March 31, 2017.

On consolidated basis, the company has reported net profit of Rs 178.61 crore for the quarter ended March 31, 2018 as compared to net loss of Rs 61.79 crore for the corresponding quarter in the FY17. Total consolidated income of the company rose 3.69% at Rs 3,737.98 crore for quarter under review as compared to Rs 3,604.79 crore for the same quarter ended previous year.

For the year ended March 31, 2018, the company has posted a rise of 50.63% in its net profit at Rs 1,468.52 crore as compared to Rs 974.94 crore for the previous year. Total income of company increased 6.08% at Rs 11,779.69 crore for year under review as compared to Rs 11,104.43 crore for the year ended March 31, 2017.

For the year ended March 31, 2018, on the consolidated basis, the company has posted rise of 40.16% in its net profit at Rs 1,410.53 crore as compared to Rs 1,006.39 crore for the previous year. Total consolidated income of company increased by 4.83% at Rs 15,576.90 crore for year under review as compared to Rs 14,858.93 crore for the year ended March 31, 2017.

Cipla Share Price

1438.75 -2.95 (-0.20%)

10-Jul-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1935.25
Dr. Reddys Labs.	1245.50
Cipla	1438.75
Zydus Lifesciences	1150.50
Lupin	2496.05
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.